Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StromaForte for Cardiovascular Event Prevention
NCT06087848Phase 2Recruiting
- Sponsor
- Cellcolabs
- Start
- Oct 2023
- Primary completion
- Oct 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of StromaForte in cardiovascular diseases (CVD), sponsored by Cellcolabs. Primary endpoint: Number of adverse events or severe adverse event assessed by CTCAE at 28 days. Started Oct 2023; status: recruiting.
02
Drugs
StromaForte
03
Conditions
cardiovascular diseases (CVD)
Beyond the preview
Go deeper on NCT06087848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087848.